Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:Drug-induced interstitial lung disease (DILD) is an increasingly common cause of morbidity and mortality. However, due to the lack of specificity, DILD detection remains an unsolved public health challenge.Objectives:For the first time, we aimed to examine DILD reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to identify demographic characteristics and top drugs associated with DILD at a group level (including age, sex, drug class, and country stratification) and individual drug level.Design:A retrospective analysis of the FAERS database was examined by disproportionality analysis.Methods:We reviewed the FAERS database from 2004 to 2021, using search terms 'interstitial lung disease' and sorting cases by generic drug name. The reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network were calculated as the measure of strength of association.Results:There were 32,821 DILD reports in the FAERS. After excluding reports without age, sex, or country data according to the specific measurement, the median age of patients was 68 (interquartile range: 59), 54.77% were male, and 46.00% of reports came from Japan. The top drug classes related to DILD in the FAERS were antineoplastic, followed by cardiovascular and antirheumatic agents, in varying order in different sexes. Fam-trastuzumab deruxtecan-nxki, ramucirumab, and eribulin were the top three drugs with the highest strength of association. We also found some drugs without DILD in the labels, such as amiodarone, temsirolimus, and ursodiol. There are significant differences in DILD reports in various countries. For example, the United States and France reported more cardiovascular agents, whereas Canada reported more antirheumatic agents.Conclusion:We found the top drugs and drug classes that were associated with DILD in the FAERS, which provides a real-world window for different ages, sexes, and countries to formulate precise pharmacovigilance policies.Plain language summaryA study on drug-induced interstitial lung diseaseIntroduction: The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database is the largest public database for spontaneous reporting of adverse events, any undesirable experiences that occur while taking a medication. The FDA designed the FAERS database to allow them to track the safety of drugs once they are released on the market. This study aims to explore drug-induced interstitial lung disease (DILD) reporting trends, demographic characteristics, most commonly reported drugs, and high strength of association drugs using the FAERS database.Methods: We retrieved the term 'interstitial lung disease' to extract DILD reports in the FAERS database from 2004 to 2021. Then, we not only counted basic patient information, including age, gender, and reporting country, but also analyzed the drug class, the reporting frequency of drug, and the degree of relevance.Results: We identified a total of 32,821 DILD reports. DILD reports had a persistent increase from 2004 to 2021. The top three drug classes related to DILD in the FAERS were antineoplastic, cardiovascular and antirheumatic agents. The top three reported drugs associated with DILD were methotrexate, doxorubicin, and pembrolizumab. The top three drugs with the highest strength of association were fam-trastuzumab deruxtecan-nxki, ramucirumab, and eribulin. Various countries have significant differences in drugs related to DILD.Conclusion: By analyzing data from the FAERS database, we identified the top drugs, drug classes, and some unexpected drugs without DILD in the labels. Our findings provide additional insight into DILD to inform clinicians to enhance monitor related to drugs of potential importance.

Drug-induced spontaneous coronary artery dissection: Analysis of the World Health Organization's pharmacovigilance database

Genome-wide association meta-analysis of spontaneous coronary artery dissection identifies risk variants and genes related to artery integrity and tissue-mediated coagulation

Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database

Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase®

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database

Demographic, clinical characteristics, managements strategies and in-hospital outcomes of patients enrolled in prospective nationwide SCAD registry

A review of the risk and precipitating factors for spontaneous coronary artery dissection

A Global Pharmacovigilance Perspective

A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases

A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies

Management of spontaneous coronary artery dissection: Trends over time

Advances in the Management of Spontaneous Coronary Artery Dissection (SCAD): A Comprehensive Review

Spontaneous coronary artery dissection: A review of medical management approaches

Spontaneous coronary artery dissection (SCAD): A contemporary review

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

Spontaneous coronary artery dissection (SCAD) with cardiac arrest at presentation: A subanalysis from the DISCO registry

Spontaneous coronary artery dissection in the context of tamoxifen; Is there any correlation?

Spontaneous Coronary Artery Dissection in Clinical Practice: Pathophysiology and Therapeutic Approaches

Spontaneous coronary artery dissection in women in the generative period: clinical characteristics, treatment, and outcome—a systematic review and meta-analysis

Prescribed Drug Use and Aneurysmal Subarachnoid Hemorrhage Incidence: A Drug-Wide Association Study

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021